'Conjugate vaccine' presentation slideshows

2009 NY/NJ Pediatric Board Review Course

1.66k views • 157 slides

Vaccines for Streptococcus pneumoniae

738 views • 48 slides

Dr. Harold J. Jennings NRC-IBS

A Canadian Success Story: Overcoming scientific and logistical problems in the development of NeisVac-C. Dr. Harold J. Jennings NRC-IBS. Age specific rates for meningococcal infection UK, Public Health Laboratory Services. Compiled by D. Jones.

504 views • 39 slides

Fever in Children

Fever in Children. Jay Hescock M.D. Assistant Professor of Pediatrics LSU Department of Pediatrics. Objectives. Review etiologies of fever without a localizing source in the pediatric population

574 views • 38 slides

National Immunization Program (NIP) Overview Stephen L. Cochi, MD, MPH

National Immunization Program (NIP) Overview Stephen L. Cochi, MD, MPH Acting Director, National Immunization Program Centers for Disease Control and Prevention National Vaccine Advisory Committee June 2004. Successes - 2004 -. Expansion of Hepatitis A Vaccine Recommendations. Source:

726 views • 33 slides

VACCINATION IN CHILDHOOD MALIGNANCY

VACCINATION IN CHILDHOOD MALIGNANCY. Prof. Mervat A Hesham 2010. To Vaccinate or Not To Vaccinate?. All vaccination decisions should be based on the benefit from vaccine (immunity) versus the risk from the vaccine (adverse reaction)

562 views • 32 slides

Immunization Update

Immunization Update. Winton G. King, M.D. Region III Medical Consultant Job Corps Health and Wellness Conference June 7, 2005. Presentation Outline. Overview of Immunization Program TagB CDC Guidelines for Children, Adolescents, and Adults VFC Program Proposed Changes New Vaccines.

443 views • 25 slides

Prevnar 13 for Adult Use Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM 197 Protein)

Vaccines and Related Biological Products Advisory Committee Meeting November 16, 2011. Prevnar 13 for Adult Use Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM 197 Protein). Applicant: Wyeth Pharmaceuticals, Inc Nicolette deVore, Ph.D. Regulatory Reviewer

1.56k views • 22 slides

EPIDEMIOLOGICAL INVESTIGATION OF S.PNEUMONIAE INVASIVE INFECTIONS IN ARGENTINIAN CHILDREN

EPIDEMIOLOGICAL INVESTIGATION OF S.PNEUMONIAE INVASIVE INFECTIONS IN ARGENTINIAN CHILDREN. PARTICIPANT INSTITUTIONS HOSPITAL CITY. SOR LUDOVICA CHILDREN HOSPITAL LA PLATA P. GARRAHAM CHILDREN HOSPITAL B. AIRES

332 views • 19 slides

Innovations in molecular diagnostics to enhance meningitis surveillance

Innovations in molecular diagnostics to enhance meningitis surveillance. Xin Wang Ph. D and Leonard Mayer Ph. D Meningitis Laboratory DBD/MVPDB/CDC. Meningitis epidemics in the meningitis belt of sub-Saharan Africa -the highest incidence (up to 1000 per 100, 000 population) in the belt

414 views • 16 slides

Introduction of a Men A conjugate vaccine: How will this change meningitis in Africa?

Introduction of a Men A conjugate vaccine: How will this change meningitis in Africa? GEO Meningitis Environmental Risk Consultative Meeting Geneva, 26-27 September, 2007. F Marc LaForce, MD. Outline of Presentation. How does Neisseria meningitidis spread in a population?

256 views • 16 slides

Introduction of a Men A conjugate vaccine: How will this change meningitis in Africa?

Introduction of a Men A conjugate vaccine: How will this change meningitis in Africa? GEO Meningitis Environmental Risk Consultative Meeting Geneva, 26-27 September, 2007. F Marc LaForce, MD. Outline of Presentation. How does Neisseria meningitidis spread in a population?

280 views • 16 slides

Global Conjugate Vaccine Market Research and Forecast, 2018-2023

Global Conjugate Vaccine Market, Size, Share, Market Intelligence, Company Profiles, Market Trends, Strategy, Analysis, Forecast 2018-2023

131 views • 12 slides

Primary Immunogenicity Endpoints for New Infant Pneumococcal Conjugate Vaccines

Primary Immunogenicity Endpoints for New Infant Pneumococcal Conjugate Vaccines. Vaccines and Related Biological Products Advisory Committee Meeting. Prevnar 13 Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]. Lucia H. Lee, M.D. CBER, FDA November 18, 2009. Overview.

292 views • 10 slides

Global Haemophilus B Conjugate Vaccine Industry 2015 Market

The report firstly introduced the Haemophilus B Conjugate Vaccine basics: definitions, classifications, applications and industry chain overview; industry policies and plans; product specifications; manufacturing processes; cost structures and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, capacity utilization, supply, demand and industry growth rate etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis. The report includes six parts, dealing with: 1.) basic information; 2.) the Asia Haemophilus B Conjugate Vaccine industry; 3.) the North American Haemophilus B Conjugate Vaccine industry; 4.) the European Haemophilus B Conjugate Vaccine industry; 5.) market entry and investment feasibility; and 6.) the report conclusion. View more details at: http://www.bigmarketresearch.com/global-haemophilus-b-conjugate-vaccine-industry-2015-research-report-market

254 views • 9 slides

Conjugate Vaccine Market - Predicted to Rise at a Lucrative CAGR throughout 2017 to 2025

The global conjugate vaccine market can be classified on the basis of product type, disease indication, pathogen type, patient type, and region. In terms of product type, the global conjugate vaccine market can be segmented into multivalent conjugate vaccines and monovalent conjugate vaccines.

81 views • 5 slides

Vaccine Conjugates Market 2018 Booming Healthcare Industry by 14.5 % CAGR till 2027 with Most Demanding Players

Market Research Future has declared the expansion of the "Worldwide Vaccine Conjugates Market Research Report which gives Market Size, Shares and Forecasts till 2027.

32 views • 3 slides

Carbohydrate Conjugate Vaccine

Carbohydrate Conjugate VaccineCarbohydrate Conjugate VaccineCarbohydrate Conjugate VaccineCarbohydrate Conjugate VaccineCarbohydrate Conjugate Vaccine

32 views • 3 slides

an introduction for Carrier Protein Design

an introduction for Carrier Protein Designan introduction for Carrier Protein Designan introduction for Carrier Protein Designan introduction for Carrier Protein Designan introduction for Carrier Protein Designan introduction for Carrier Protein Design

34 views • 3 slides

Pneumococci Transmission Dynamics:

Vaccine Serotypes. Percent. Vaccine Effect. 20%. b nv V. V. Timing. b v X. Pre 98 99. Post 03 04. 15%. f v V. Colonized with both. V NV. X. Not Colonized. 10%. f nv NV. 5%. b v NV. NV. b nv X. 0%. 19. 14. 23. 6b. 9v. 18. 4. 19. 6. 23. 9. 1. 10. 11. 12.

103 views • 1 slides